Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 742-745 |
| Number of pages | 4 |
| Journal | Cancer Cell |
| Volume | 37 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 8 Jun 2020 |
Access to Document
- 10.1016/j.ccell.2020.05.008Licence: Free access - publisher
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer Cell, Vol. 37, No. 6, 08.06.2020, p. 742-745.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
AU - Whisenant, J.G.
AU - Trama, A.
AU - Torri, V.
AU - De Toma, A.
AU - Viscardi, G.
AU - Cortellini, A.
AU - Michielin, O.
AU - Barlesi, F.
AU - Dingemans, A.M.C.
AU - Van Meerbeeck, J.
AU - Pancaldi, V.
AU - Soo, R.A.
AU - Leighl, N.B.
AU - Peters, S.
AU - Wakelee, H.
AU - Garassino, M.C.
AU - Horn, L.
N1 - Funding Information: A.C. reports grants and personal fees from MSD, grants from Roche, grants from BMS, grants and personal fees from Astra-Zeneca, grants from Novartis, and personal fees from Astellas outside the submitted work. S.P. has received education grants, provided consultation, attended advisory board meetings, and provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports a leadership role in IASLC. M.C.G. reports personal fees from Bayer, personal fees and other from Eli Lilly, personal fees from Boehringer Ingelheim, personal fees from Otsuka Pharma, Seattle Genetics and Daiichi Sankyo, personal fees and other from Astra Zeneca, personal fees and other from Novartis, personal fees and other from BMS, personal fees and other from Roche, personal fees and other from Pfizer, personal fees and other from Celgene, personal fees from Incyte, personal fees from Inivata, personal fees from Takeda, other from Tiziana Sciences, other from Clovis, other from GSK, personal fees from Sanofi-Aventis, and other from Spectrum Pharmaceutcials, Blueprint Medicine outside the submitted work. L.H. reports consulting for Astra Zeneca, Incyte, Amgen, EMD Serono, Bayer, Merck, Pfizer, Genentech-Roche, and Xcovery and research funding from Bristol Myers Squibb, Xcovery, and Boehringer Ingelheim. No other authors have disclosures to report. Funding Information: The authors would like to thank all TERAVOLT consortium investigators and the ESMO, IASLC, ETOP, and ERS scientific societies. REDCap is supported by the National Institutes of Health ( UL1 TR000445 ). Funding Information: The authors would like to thank all TERAVOLT consortium investigators and the ESMO, IASLC, ETOP, and ERS scientific societies. REDCap is supported by the National Institutes of Health (UL1 TR000445). A.C. reports grants and personal fees from MSD, grants from Roche, grants from BMS, grants and personal fees from Astra-Zeneca, grants from Novartis, and personal fees from Astellas outside the submitted work. S.P. has received education grants, provided consultation, attended advisory board meetings, and provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports a leadership role in IASLC. M.C.G. reports personal fees from Bayer, personal fees and other from Eli Lilly, personal fees from Boehringer Ingelheim, personal fees from Otsuka Pharma, Seattle Genetics and Daiichi Sankyo, personal fees and other from Astra Zeneca, personal fees and other from Novartis, personal fees and other from BMS, personal fees and other from Roche, personal fees and other from Pfizer, personal fees and other from Celgene, personal fees from Incyte, personal fees from Inivata, personal fees from Takeda, other from Tiziana Sciences, other from Clovis, other from GSK, personal fees from Sanofi-Aventis, and other from Spectrum Pharmaceutcials, Blueprint Medicine outside the submitted work. L.H. reports consulting for Astra Zeneca, Incyte, Amgen, EMD Serono, Bayer, Merck, Pfizer, Genentech-Roche, and Xcovery and research funding from Bristol Myers Squibb, Xcovery, and Boehringer Ingelheim. No other authors have disclosures to report. Publisher Copyright: © 2020
PY - 2020/6/8
Y1 - 2020/6/8
N2 - Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.
AB - Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.
U2 - 10.1016/j.ccell.2020.05.008
DO - 10.1016/j.ccell.2020.05.008
M3 - Editorial
C2 - 32425702
SN - 1535-6108
VL - 37
SP - 742
EP - 745
JO - Cancer Cell
JF - Cancer Cell
IS - 6
ER -